The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study.
Patrick B. Johnston
Consultant or Advisory Role - Novartis (U)
Lauren C. Pinter-Brown
No relevant relationships to disclose
Jaqueline Willemann Rogerio
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ghulam Warsi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Quincy Chau
No relevant relationships to disclose
Rod Ramchandren
Honoraria - Seattle Genetics